TOP2A and cancer: Our results identified a 3% mutation rate of TOP2A in all 10953 tested cancer patients, and TOP2A mutation was significantly associated with poor overall survival, disease-specific survival, and progression-free survival in patients with ovarian serous cystadenocarcinoma, while the associations between TOP2A mutation with survival prognosis of other cancers needs to be further investigated.